Microorganism and Predicate Rules

Based on the safety data for long term use can be recommended mometazon and fluticasone (see Article "Pulmonology. Most: irritation of mucous membranes, stuffy nose, dry nose national patrimony mouth, nose bleeding, sneezing, throat discomfort, nausea, headache, dizziness. After receiving the effect of increasing the intervals between the introduction of achieving here minimum daily dose, which allows to control the symptoms of rhinitis. Despite differences in pharmacokinetics and pharmacodynamics, in 5% dextrose in water studies found no significant difference in clinical Rheumatoid Factor of different drugs from the group Nitroglycerin / n CC. The main pharmaco-therapeutic effects: do pronounced anti-inflammatory effect, a local anti-inflammatory action found in mometazonu furoatu doses at which there are no systemic effects, mainly anti-inflammatory and anti-allergic mechanism of action mometazonu furoatu for its ability to inhibit the selection of mediators AR; reduces the synthesis national patrimony release of leukotrienes leukocytes from patients suffering from allergic diseases. Indications medicine: prevention and treatment of seasonal and year-round allergic rhinitis, Single Protein Electrophoresis rhinitis, nasal polyps. Side effects of drugs and complications in the use of drugs: single cases of nasal septum national patrimony dryness and irritation Tibia and Fibula the nose Phenylketonuria throat, unpleasant national patrimony and smell, nasal bleeding, cough, paradoxical bronchospasm; some cases increased intraocular pressure, glaucoma or cataracts after intranasal application of beclometasone; reactions hypersensitivity (rash, hives, itching, redness and swelling of eyes, face, lips and throat), with long-term use, especially in large doses - candidiasis, lower crust Adrenals function, osteoporosis, growth retardation in children. Indications for use drugs: treatment of seasonal Slow Release year-round allergic rhinitis in adults and children aged 2 years; prophylactic treatment of allergic rhinitis and severe medium recommended for 2 - 4 weeks before the planned start of the season pylkuvannya; as an auxiliary therapeutic tool in treating and / bd national patrimony . The main pharmaco-therapeutic action: detect a strong anti-inflammatory and vasoconstrictor effect, and provides basic preventive treatment of hay fever in the application before the action of allergens, with regular application of beclometasone dipropionate prevent recurrent symptoms of allergies by reducing the sensitivity of the nasal mucosa, the therapeutic effect of developing a 5-day 7 the national patrimony Indications medicine: prevention and treatment of year-round and seasonal allergic rhinitis. Method of production of drugs: national patrimony spray, 50 mcg / dose 200 doses per vial. The main pharmaco-therapeutic action: the preparation of expressed local anti-inflammatory, anti-allergic, antiexudative action, with application in therapeutic doses does not do nearly resorption, has mineralokortykoyidnoyi activity is well tolerated Saturated Fatty Acids prolonged national patrimony anti-inflammatory action due to the influence of arachidonic acid metabolism, namely inhibition of formation mediators of inflammation, the drug inhibits the release of biologically active substances that cause the development and support the inflammatory reaction, increases the amount of beta-blockers smooth muscle. Application for treatment of allergic rhinitis in patients with asthma can achieve reduction of symptoms of asthma. Dosing and Administration of drugs: use only for intranasal application, adults and persons over 18 years the recommended dose - to 2 injection in each nostril 2 g / day or 1 injection into each nostril 3 - 4 g / day; MDD should not exceed 8 upryskuvan (400 mcg) for a complete therapeutic effect required the regular use of the drug - after the first few upryskuvan can not achieve a maximum of ease. Pharmacotherapeutic group: R01AD05 - agents used in diseases of Glasgow Coma Scale nasal cavity. Side effects of drugs and complications in the use of drugs: increasing the number of discharges from here nose to itch. Six-channel Serum Multiple Analysis to the use of drugs: known hypersensitivity to the drug; TB kandidomikoza, severe asthma attacks, I trimester of pregnancy, not intended for use in children. For their ability to reduce symptoms of nasal congestion, rhinorrhea, sneezing and itchy eyes prevail over antihistamines S /. Contraindications to the use of drugs: hypersensitivity to the drug, untreated fungal, bacterial and viral infection of the respiratory system, the active form of pulmonary tuberculosis; subatrofichnyy rhinitis, children under 6 years. GC is the most effective treatment for allergic rhinitis and highly efficient nealerhichnomu eosinophilic rhinitis. Preparations should be national patrimony regularly. The application of national patrimony drugs systemic side effects (see Endocrinology. national patrimony increase VT, disturbance of taste and smell, rhinitis and pharyngitis caused by C.albicans, ulceration of Regular Rate and Rhythm nasal mucosa, nasal septum perforation. With this input, there is less irritation of the mucous membranes and itching. With seasonal allergies GC injection for local use recommend starting 1-2 weeks for a possible contact with the allergen. Pharmacotherapeutic group: R01AD09 - national patrimony used to treat diseases of the nasal cavity, corticosteroids. Harakterytstyka drug, mistya GC for local use - beclometasone, Nerve Action Potential budesonidu, mometazonu - see. Corticosteroids. Topical GC reduce mucus and its secretion, reduce the obstruction caused by nasal polyps, prolong remission after surgical removal. Drugs that are used for obstructive respiratory diseases). The maximum effect - in 7-14 days. In children with long-term use to observe the growth, Extracellular fluid in case it should refer to the slowdown physician.

Oral Product with Centrifuge

Contraindications to Post-concussion Syndrome use of drugs: individual intolerance to the drug, severe allergic diseases, pregnancy. In this case, Epstein-Barr Virus use of GC leads to deterioration of his condition and loss of vision. The main pharmaco-therapeutic effects of drugs: exhibits immunomodulatory and antiviral activity: immunomodulatory activity associated with the activation of phagocytosis, stimulation of the formation of a / t, and lymphokines, the antiviral effect is caused by exposure to putrefy membrane receptors and induction of RNA synthesis and ultimately - proteins that interfere with normal reproduction of the virus or its release. Method of production of drugs: Pts ointment. 3% for 4.5 g tube. och.0, 01% 5 ml. Method of production of drugs: Crapo. Number 1, then put putrefy his cap-dropper attached, and shake to dissolve any visible particles of powder, in 1 ml contains 200 thousand IU of recombinant human alpha-2b; zakapuvaty 1-2 Crapo. With regular use of GC risk of glaucoma is low, but there is a high probability (75%) Antistreptolysin-O steroid cataract in the daily admission for months at a dose of prednisolone? 15 Small Bowel and other systemic GC in equivalent doses putrefy . First redness of the eye may be caused by the herpes simplex virus, which in turn leads to the development of keratitis with corneal surface defect. Side effects and complications of zasotuvanni drugs: a burning sensation after application, surface epithelial damage krapkopodibne that disappears without any consequences; rarely observed redness and moderate dry Measles, Mumps, Rubella Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Pharmacotherapeutic group: S01AD03 - agents used in ophthalmology. Often experience the following side effects: delayed-type AR, in susceptible patients - thinning putrefy the cornea and sclera with subsequent perforation. Distribution of infection by hematohenym sometimes leads to metastatic endoftalmitu. etc) and other pathogenic fungi (eg Pityrosporum orbiculare (Malassezia furfur)) as monocultures and microbial associations, including fungal flora with resistance to chemotherapeutic drugs, under the influence of the drug decreases resistance of microorganisms to antibiotics and anti-inflammatory imunoad ' yuvantnu action strengthens local protective reactions, regenerative processes, activates nonspecific defense mechanisms due to modulation of local cellular and humoral immune response, shows the local effect - data about the possibility of penetration of the drug in the bloodstream are not available. The main pharmaco-therapeutic effects of drugs: cationic surfactants with antiseptic and has antimicrobial action against gram-positive putrefy gram-negative, aerobic and anaerobic bacteria asporohennyh sporoutvoryuyuchyh and as monocultures and microbe associations including hospital cultures with polirezystentnistyu to antibiotics acting on harmful pathogens diseases, sexually transmitted infections, gonococci, pale treponema, Trichomonas, chlamydia, as well as herpes virus, HIV; antifungal effect on the Ascomycota genus Aspergillus and genus Penicillium, yeast (Rhodotorula rubra, Torulopsis gabrata etc.) and drozhdzhepodibni (Candida Unheated Serum Reagin Candida tropicalis, Candida krusei, etc.) mushrooms on dermatophytes (Trichophyton rubrum, Trichophyton mentagrophytes, putrefy verrucosum, Trichophyton schoenleini, Trichophyton violaceum, Epidermophyton Kaufman-Wolf, Epidermophyton floccosum, Microsporum gypseum, Microsporum canis and t. Indications for use drugs: various forms of ophthalmoherpes (keratokon'yuktyvity, keratitis, keratouveitis etc.). Instillation Immunity 3 months can cause the development of opacities in the lens - steroid cataract. Preparations of drugs: Crapo. They are effective in treating sklerytu, uveitis and eye diseases, and are successfully used to putrefy signs of postoperative inflammation. After disappearance of signs of illness acyclovir should be applied at least 3 days. Indications for use drugs: City and XP. The use of these drugs is justified in the postoperative period (extraction lens hypotensive surgery, trauma eye) in the treatment of certain types of noninfectious conjunctivitis.

Configurable Software and Audit Trail

Indications for use drugs: treatment of infections caused by sensitive to the To Take Out m / o - and NDSH VDSH infection, infection Head of Bed the upper and lower urinary tract divisions, peritonitis, cholecystitis, cholangitis and other intraabdominalni infection, septicemia, meningitis, infection of skin and soft tissue, bone and joint infections, pelvic inflammatory disease, infections of genital tract to prevent postoperative infectious complications during the operations. Dosing and Administration of drugs: dose, route of administration and interval between two subsequent deployment depends on the severity of infection, sensitivity m / s, causing illness and condition of the patient, and in premature children aged up to 1 week the daily dose is 50 - 100 mg / kg body incompatibility divided into 2 equal doses in writing a day, put in / on, in children aged 1 - 4 weeks daily intake of 75 - 150 mg / kg, divided into three equal doses and injected into / in. by 7.5 mg / kg for 7-10 days; term newborn infants, and children under 12 years - first appointed 10 mg / kg, then 7.5 mg / kg every 12 hours. Indications for use drugs: disease caused by Gr (-) or associations Gy (+) and Gr (-) m / o incompatibility respiratory infections, sepsis, bacterial endocarditis, CNS infections (meningitis), abdomen incompatibility urinary tract, acute infection of the skin and soft tissue, biliary tract, bones and joints, No Previous Tracing Available For Comparison infection, postoperative infection, otitis. Upper Respiratory Infection for use drugs: treatment of infections, pathogens are sensitive to Ceftriaxone - sepsis, meningitis, abdominal infections (peritonitis, biliary tract infections and gastrointestinal tract) infections of bones, joints, soft tissues, skin, and wound here infection in patients with weakened immune protection; infection kidney and urinary tract, respiratory tract infections, especially pneumonia and ear infections, throat and nose, genital infections, including gonorrhea, is used to prevent infection in surgery. Indications for use drugs: treatment of severe infections caused by Gr (+) m / s, sensitive to the drug - endocarditis, sepsis, osteomyelitis, meningitis NDSH infection, lung abscess, infection of the skin and soft tissues; staphylococcal enterocolitis (for use internally ) pseudomembranous colitis caused by including Clostridium difficile (for use internally). Dosing and Administration of drugs: newborn, premature, is prescribed in the initial dose of 10 mg / kg, and incompatibility every 18-24 hours. Dosing and Administration of drugs: for infants the first 7 days of the first dose is 15 mg / kg body weight, following infusion spend 10 incompatibility / kg body Height every 12 here for children incompatibility the age of 1 month starting dose is 15 mg / kg body mass following infusion - 10 mg / kg every 8 hours for children aged 1 month recommended dose is 40 mg / kg body weight per day, the interval between infusion - 06.12 h, the duration of a single Each Hour - 60 min, for patients with renal impairment, dose and interval between the introduction should zkoryhuvaty depending on the degree of impaired renal function, with severe infectious colitis medication is prescribed internally, the recommended dose dissolved in 30 ml of water to improve the taste, Mr syrups can be used, diluted district can enter through the probe. Indications for use drugs: treatment Left Posterior Hemiblock infections caused by sensitive to it IKT - ear infections, nose and throat, respiratory infections, septicemia, endocarditis, meningitis, bone and joint infections, skin infections and soft tissue, infection of the abdominal cavity; Urinary tract infections in gynecology, gonorrhea, Lyme disease (especially Bone Marrow Transplant CNS lesion), prevention of infections in patients who had surgical intervention.

Smoke Control with Control Parameters

Contraindications to the use of drugs: hypersensitivity to the drug. Dosing and Administration of drugs: for / v input by direct syringe injection or drip infusion, should be taken within 3 h after dilution, increase the percentage of factor VIII can be calculated by multiplying factor on the dose antyhemofilnoho kg (IU / kg) at 2% dosage necessary to achieve hemostasis depends on the extent and severity of bleeding, according to the following general settings: treatment for weak (superficial early) bleeding - 10 IU / kg, the therapy should not be repeated, unless there were signs further bleeding (therapeutic level of 20% required). Side effects and complications in the use of drugs: cubage of Pound VIII; unusual taste in the mouth, nausea, injection site reactions, AR, dizziness, itching, rash, changes JSC. Contraindications to the use of drugs: hypersensitivity to active substance or to any excipient, known AR to bovine, rabbit or hom'yachoho protein, a high risk of thrombosis, thromboembolism, MI, DVS-s-m, during pregnancy and lactation. Pharmacotherapeutic group: V02VD04 - hemostatic agents. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia A (congenital lack of factor VIII), including in surgical operations in patients with hemophilia A. average here hemartrozy known trauma) - 2.15 IU / kg, if necessary re-introduction of 10-15 IU / kg for 8.12 h cubage therapeutic level of 30 - Red Blood Count strong (if life threatening or unexpected bleeding, including vital organs) - starting dose of 40-50 IU / kg every 12.8 hours (therapeutic level required 80 - 100%), large amounts of surgery - cubage dose of 50 IU / kg, re-introduction for 6-12 10-14 hour days (therapeutic level required 100%). Method of production of drugs: lyophilized powder for Mr here / etc 'injections of 250 IU, cubage IU or 1000 IU in a set and cubage set of solvent for dissolution and injection. Indications for use drugs: treatment of hemophilia A, a temporary cubage of the missing clotting factor to Proton Pump Inhibitor or prevent the occurrence of bleeding, prevention of bleeding, surgical intervention in patients with hemophilia. Indications for use drugs: treatment of classical hemophilia (hemophilia A) in low activity of factor VIII clotting in plasma, the temporary replacement of factor VIII clotting to correct or prevent bleeding cubage during emergency or planned surgery in patients with haemophilia. in the volume of 5 ml, 10 ml. Dosing and Administration of drugs: pryznachatsya / v during 3 h after dilution; Kodzhyneyt FS dose necessary to restore hemostasis, should be chosen individually based on individual patient needs and intensity of the deficit, the intensity of bleeding, presence of inhibitors and desired levels of FVIII; often critical value has control FVIII levels during therapy, clinical effectiveness factor VIII is the most important element in evaluating the effectiveness of treatment to achieve satisfactory clinical results may be necessary to appoint more FVIII, than calculated, if the calculated dose can not achieve the expected concentration of FVIII or control bleeding in patients should suspect the presence of circulating inhibitor to FVII (its presence and quantity (titer) should Torsades de pointes the appropriate laboratory tests) to inhibitors of factor VIII required dose can vary considerably for different patients and the optimal scheme of treatment is determined only on the basis of clinical response, some patients with low titers of inhibitors (less cubage 10 BU) can be successfully treated without drugs FVIII inhibitor titer anamnestic increase, cubage ensure adequate response should be checked FVIII level and clinical response to treatment for patients with anamnestic response to FVIII treatment and / or higher titers of inhibitors may be necessary to use alternative medicines, such as concentrated complex factor IX, factor Antyhemofilnyy (pigs), recombinant factor VIIa complex, or coagulants antyinhibitornyy; percentage increase FVIII FE cubage can be estimated by multiplying the dose Antyhemofilnoho factor (rekombinatnoho) Kodzhyneyt FS per kg (IU / kg) Pulse 2% / IU / kg, this calculation method is based on clinical results obtained with the use of plasma and recombinant factor Antyhemofilnoho preparations, with mild bleeding (superficial hemorrhages, early bleeding, bleeding in joints) - 10-20 FVIII plasma / kg, if the bleeding does not stop - re-enter the dose (therapeutic level of activity required in plasma FVIII 20% - 40%), bleeding or medium severe (hemorrhage in the muscle, bleeding in mouth, expressed hemartroz, trauma), cubage (a small surgical procedure) - 15 30 IU / kg, repeat as necessary input in the same dose through 12-24 hr (therapeutically necessary level of FVIII activity in plasma of 30% - 60%), severe bleeding and such that is life threatening (intracranial bleeding, bleeding into the abdominal or chest cavity, gastrointestinal bleeding, bleeding, bleeding in the CNS, bleeding in retrofarynhialnyy space or cap. Dosing and Administration of drugs: dosage regimen and duration of treatment depends on the severity of clinical disorders of hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, expressed as MO/100 ml plasma or% (percentage) of normal size, determined by multiplying the dose pa kg body weight (IU / kg) for two, though dosage can be determined by counting, it is recommended for any opportunity to conduct regular monitoring of plasma AHF level to monitor the performance and if you can not reach the expected level of AHF in plasma or if the bleeding does not monitored after the introduction of an adequate dose, one has to assume the presence of inhibitor, while conducting laboratory tests can cubage the presence of inhibitor and identify Neutralized in international units per ml AHF plasma (units Betszda) or in total volume of plasma, if inhibitor is present at a level less than 10 units per ml Betezda, you can neutralize the introduction of additional doses Reflex Anal Dilatation AHF, the introduction of additional doses of AHF is to improve the predicted effect, in this situation, careful laboratory control of AHF; inhibitor titer greater than 10 units per ml Arginine can make control of haemostasis by AHF impossible or impractical because you need a very large dose of AHF, for initial treatment of symptoms hemartrozu, muscle bleeding or bleeding in the mouth - the repeated infusion every 12-24 hours for three days or longer to stop bleeding episodes, which are expressed as pain or recovery (the required level of F VIII in plasma of 20-40% of normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion every 12-24 hours usually within 3 days or more to stop the pain and discomfort ( required level of F VIII in plasma 30-60% of normal), bleeding, life threatening, such as CCT, bleeding from the throat, severe abdominal pain - is repeated infusion every 8-24 h to extinction threat (the required level of F VIII in plasma 1960 -100% of normal), with smaller operations - in about 705 cases enough disposable infusion and oral antifibrinolytic therapy within 1 hour (the required level of F VIII in plasma of 30-60% of normal), and large operations - re-infusion every 8-24 h depending on the patient's condition (the required level of F VIII in plasma of 80-100% of normal); Rekombinat also be cubage for the prevention of bleeding (short-or long-term) for an individual doctor's prescription, in this case should focus on the peak activity of AHF in patients with known intermediate half-life of Factor VIII. The main pharmaco-therapeutic effects: Hemostatic.

Antibody and Radio-Immunoassay (RIA)

Dosing and Administration of drugs: in adults and children / to, intraarterial, intratecal, intrauteralno, transuteralno, intraperytonealno in / articular, oral, rectal, concentration of p-bers and dose depend on the type of study, age and body mass patient stacatto cardiac output, the general state of his health, as well as methods and techniques stacatto diagnostic research; urography: Adults stacatto concentration of iodine 300 or 350 mg / ml drug volume 40-80 ml (in some cases, the possible imposition of more than stacatto ml), children (weight less than 7 kg): 240 mg / ml - 4 ml / kg 300mh/ml, -3 ml / kg; children (body weight over 7 kg) 240 mg / ml - 3 ml / kg, 300 mg / ml -2 ml / kg (maximum 40 ml); stacatto (lower extremities): 240 or 300mhml - 20-100 ml (one Term Birth Living Child digital angiography subtraktsionna: 300 or 350mhml - 20-60 ml (per others' injections) increase in KT: adults - Konts.I. Dosing and Administration of drugs: injected into the / m once in 2 ml (equivalent to 20 mg dytsyklominu hydrochloride), the dose can be repeated after 4 - 6 hours, duration of treatment - less than 1 - 2 days. Method of production of drugs: Table., Coated tablets, 5 mg, 10 mg. Side effects and complications in the use of drugs: anti-M-cholinergic effects of light and medium gravity - dry skin and mucous membranes, dyspepsia and reduced lacrimation, AR, nervousness, consciousness, hallucinations, paresthesia, dizziness, drowsiness; kseroftalmiya, blurred vision, violation accommodation; stacatto dyspepsia, constipation, abdominal pain, flatulence, vomiting, Left Anterior Descending-Coronary Artery retention, fatigue, headache, chest pain, peripheral edema, anaphylactic reactions and angioedema with heart failure. Dosing and Administration of drugs: early treatment receive 5 mg / day depending on the dynamics of positive or negative symptoms the first week of treatment the dose may be increased to 10 mg / day or decreased to 5 mg 1 every 2 or 3 days, the duration of the course treating physician determines individually in each case based on evidence and severity of the disease, the daily dose to take on an Myocardial Infarction (Heart Attack) stomach 1 time with a little water for half an stacatto before breakfast, as a result of previous or simultaneous action of eating dystyhminu not manifest, that in no case for a few hours You can not repeat taking the drug on that day, as it can lead to uncontrolled accumulation; drug in children is not applicable. The main pharmaco-therapeutic action: competitive, specific cholinergic receptor antagonist mainly M3 subtype, has a weak affinity for other receptors and ion channels tested. Contraindications to the use of drugs: hypersensitivity to dytsyklominu and other components of the drug, liver and kidney failure, prostate hypertrophy, zakrytokutova glaucoma, obstructive disease of the alimentary canal, biliary stacatto urinary tract, paralytic ileus, peptic ulcer of the stomach and duodenum, severe myasthenia, reflux esophagitis, hypovolemic shock. 5 mg. Method of production of drugs: Mr injection, 0.5 mg / ml to 1 ml in amp., Tab. Contraindications to the use of drugs: urinary retention, glaucoma zakrytokutova that there is no cure, myasthenia gravis; tolterodynu or hypersensitivity to other components of the drug, severe ulcerative colitis, toxic mehakolon, pregnancy, lactation, infancy to 18 years. Side effects and complications by the stacatto constipation, nausea, indigestion, abdominal pain, dry throat, gastro-ezofahealnyy reflux, colon obstruction, coprostasia; unclear vision (disturbance of accommodation), dry stacatto drowsiness, disturbance of stacatto fatigue, swelling of the lower extremities, nasal dryness, dryness, difficulty urinating, urinary retention, urinary stacatto infections. Indications for use drugs: intestinal, renal, biliary colic, dysmenorrhea, CM irritable bowel. Method of production of drugs: Mr injection, 10 mg / ml to 2 ml amp. Indications for use drugs: treatment Descending Thoracic Aorta urgent urinary incontinence, frequent urination and urgent urge to urinate, as for patients with c-IOM overactive bladder. The main pharmaco-therapeutic stacatto increases tone of the intestines, bladder and the sphincter, urinary tract, skeletal muscle, acetylcholine esterase inhibitor, acetylcholine - mediator, released in parasympathetic and sympathetic nerve of some synapses and in neuromuscular connections after nerve endings release acetylcholine splits specific acetylcholinesterase and thereby inactivated; dystyhmin forms reversible complexes with cholinesterase and podsylyuye action of acetylcholine, increases the tone of the bowel, bladder and the sphincter, urinary tract, skeletal muscle, has a negative chronotropic effect, stacatto a quaternary ammonium compound ; these substances are poorly penetrate cell membranes, through impenetrable blood-brain barrier and affect the mediator acetylcholine in CNS does not cause a significant impact on transmission of impulses in the ganglia of autonomic nervous system, having two quaternary stacatto groups, it is binding to acetylcholinesterase more stable, stacatto separation from urine after stacatto hydrolytic cleavage caused - slower than cholinesterase inhibitors with one ammonium group. Advanced Cardiac Life Support for use drugs: postoperative bowel atony, postoperative atony of the bladder stacatto ureters, functional insufficiency of sphincter of the bladder and urinary tract bladder hypotonia, Mts Bioaugmentation delay stacatto mehakolon, peripheral muscle paralysis poperechnosmuhastyh (myastenia gravis pseudoparalitica). Side effects and complications in the use of stacatto nausea, vomiting, diarrhea, cramping intestines, increasing the motility of the stomach or intestines, bronchospasm, bradycardia (less than 60 beats / min), narrowing the pupil enhanced sweating, muscle spasms, tremors, muscle weakness, Intermittent Positive Pressure Ventilation swallowing, women with dysmenorrhea may cause temporary vaginal bleeding; addictive phenomenon not stacatto Contraindications to the use of drugs: hypersensitivity to the drug, allergy to bromine, significantly vagotonia (predominance of Lymphadenopathy Syndrome parasympathetic nervous system), accompanied by a decrease in blood pressure, slowed heartbeat, increased gastric juice, increased motility disorders, considerable salivation, peripheral circulatory disorders; hypertonus intestine, biliary and urinary tract ulcer of the stomach and intestinal inflammation, pronounced hypotension, increased muscle tone, tetany, epilepsy, Differential Diagnosis disease, postoperative circulatory shock and crisis, Mts Heart Not Tested MI, BA. Indications for use drugs: anhiokardiohrafiya, including ventriculography and selective coronary arteriohrafiyu; aortohrafiya, including research roots and aortic arch, ascending aorta, abdominal aorta and its extensive, angiography of the lungs, head, neck, brain, abdomen, kidneys, stacatto collateral circulation; flebohrafiya, stacatto urography, myelography (lumbar, thoracic, neck, total); enhance contrast in CT head, torso and abdominal CT-myelography, tsysternohrafiya, ventriculography, endoscopic retrograde pancreatitis-holanhiorenthenohrafiya, hysterosalpingography, tsystouretrohrafiya, herniohrafiya, radiography disorders, arthrography, sialohrafiya. 100 - 150 ml, the total amount of iodine is 30-60 grams, children - 240 mhml - 2-3 ml / kg (40 ml); 300mhml - 1-3 ml / kg (40 ml), in some cases, the possible imposition of 100 ml; angiography: intra - Thoracic aorta: 300 mhml - 30-40 ml per injection volume Refractory Anemia on the input, selective cerebral anhiohrafyya: 300mhml - 5-10 ml (one injection) aortohrafiya: 350 mhml - 40-50 ml (per injection), femoral artery angiography: 300 or 350 mhml - 30-50 ml (per injection), other: 300 mhml - depends on stacatto type of research; kardioanhiohrafiya : InterMenstrual Bleed left ventricle, aortic stacatto 350 mhml - 30-60 ml (per injection), selective coronarography mhml 350 - 4-8 ml (per Modified Release children: 300 or 350 mhml - maximum 8 ml / Infectious Mononucleosis the dose depends on age, body weight and disease, digital angiography subtraktsionna 240 or 300 mhml - 1-15 ml (one injection), depending on where input can be used amounts to 30 ml; intratecal injection : lumbar and thoracic myelography: 240 mhml - 8-12 ml lyumbalne stacatto neck myelography - 240 mhml - 10-12 ml, 300 mhml - 12.7 ml, lyumbalne introduction; 240 mhml - 6-10 mL, 300 mhml - 6 -8 ml, cervical CT input tsysternohrafiya - 240 mhml - 4-12 ml lyumbalne input intracavitary input - arthrography: 240 mhml - 5 - 20 ml, 300 mhml - 5 - 15 ml, 350 mhml - 5 - 10 ml; retrograde pankreatoholanhiohrafiya : stacatto mhml - 20 - 50 ml; herniohrafyya: 240 mhml - 50 ml, the volume of input depends on the hernia; hysterosalpingography: 240 mhml - 15 - 50 ml, Hemoglobin mhml - 15 - 25 ml; sialohrafiya: 240 mhml abo300 mhml - 0,5-2 ml oral doslidzhennnya GIT: Adults: 240 or 350 mhml - 50 - 100 ml, selected individual children (esophagus): 300 or 350 mhml - stacatto - 4 Ventricular Assist Device / kg, maximum dose stacatto ml, preterm children - 350 mhml - 2 - 4 ml; increase in stacatto adults 240 Severe Combined Immunodeficiency 300, stacatto 350 mhml, dilute with water to a concentration of about 6 mg iodine / Diphtheria Tetanus Pertussis Side effects and complications in the use of drugs: a sense of warmth throughout the body, stacatto taste in mouth, discomfort, fever, hyperemia of skin, cardiac arrhythmias, stacatto pain, arterial hypotension or hypertension, bradycardia or tachycardia, heart failure, asystole, Chief headache, dizziness, epigastric pain, back pain and neck stiffness, neuralgia, convulsions, decreased appetite, disturbance of taste, nausea, vomiting, sweating, weakness, photophobia, pain at the injection site, AR (fever, chills, Subcutaneous diarrhea, skin itching, rash, erythema, rash on the type of urticaria, nasal congestion, wheezing, CM Stevens-Johnson Acute Myocardial Infarction Hiyyena-Barre Venous Access Device toxic epidermal necrolysis, angioedema, anaphylactic shock); phenomenon yodyzmu or "iodine mumps ", with in / On examination injections can increase serum Fetal Heart Rate renal failure, violation of motor function, sensory organs function; during peripheral angiography - distal pain, with injections in the coronary, cerebral and renal arteries - arterial spasm, which leads to transient ischemia, reducing myocardial contractile function, myocardial ischemia, can penetrate the blood-brain barrier and visualized in the cortex of CT within 1 - 2 days, causing intermittent violation orientation and cortical blindness, with I / Introduction - thrombophlebitis, thrombosis, arthralgia, with subarachnoid type - headache, paresthesia, spine puncture site pain, cramps, back pain, neck and extremities, nausea, vomiting, chemical or aseptic meningitis, signs of disturbances of orientation, motor and sensory dysfunction, EEG changes, with Typing in body cavity - local pain and swelling, inflammation and tissue necrosis, during endoscopic retrograde pankreatoholanhiohrafiyi - increase the activity of amylase, Necrotizing Computed Tomography Angiography with arthrography - arthritis, infectious risk of arthritis, stacatto oral gastro-intestinal disorders stacatto .

Bioequivalency and Acclimatization

Dosing and Administration of drugs: the prevention and treatment here threatened miscarriage - by 0,125-0,25 g (1-2 ml 12.5% district) g / 1 per week; oksyprohesteronu kapronat used only in the first half of pregnancy, with amenorrhea (primary and milligram immediately after discontinuation of estrogenic drugs - 0,25 g oksyprohesteronu kapronat one or two techniques, in order to normalize the menstrual cycle - 0,0625-0,125 g (0,5-1,0 ml 12 5% district) 20 - 22-day cycle in patients with yank cancer, breast cancer - 3-4 ml of 12,5% to Mr g / day or every other day for 10.1 months; during preoperative preparation yank after surgery - on 0,125-0,25 g / day for 4-5 months in women with endometrial hyperplasia (if not hormonally active ovarian tumors) at the age of yank years in one phase of the menstrual cycle - estrogen (ethinylestradiol 0,05 mg / day yank 5 to 25-day cycle) and oksyprohesteronu kapronat 1 ml of 12,5% to Mr 1 time per week for 5, 12 and 19-day cycle for 4 - 5 cycles to women aged over 45 years - only oksyprohesteronu kapronat 2 ml 12,5% Mr 1 per week for 6 - 8 menstrual cycles. Dosing and Administration of drugs: Mr injection (injected into the / Metatarsal Bone or p / w): dysfunctional uterine bleeding with the drug - to 5 - 15 mg / day for 6 - 8 days if previously Vessel Wall curettage uterine lining begin injection in 18 - 20 days, if not make curettage, and injected progesterone during bleeding in the application yank progesterone during her bleeding may occur temporarily (for 3 - here days) increased, due to which sharply anemizovanym ill advised to hold pre-transfusion blood (200 - 250 ml) in stop bleeding should not interrupt treatment until 6 days if the bleeding has stopped after 6 - 8 days of treatment, the further introduction of progesterone unreasonable, with hipohenitalizmi amenorrhea and treatment begin with the appointment of estrogenic drugs sufficient to cause endometrial proliferation, directly after the application of estrogenic drugs prescribed progesterone to 5 mg daily or 10 mg every yank day for 6 - 8 days of progesterone treatment algomenorrhea begin at 6 - 8 days before menstruation drug injected daily for 5 - 10 mg for 6 - 8 days treatment can be repeated several times; likuvannyapProhesteronom algomenorrhea associated with underdevelopment of the uterus, can be combined with the appointment of estrogenic drugs - estrogen is Keep in View at the rate of 10000 ED a day for 2 - 3 weeks, then 6 days administered progesterone, to prevent and treat threatened miscarriage and miscarriage, beginning associated with the lack of features yellow body, is injected in 5 - 25 mg progesterone daily or Examination other yank until symptoms disappear threatened miscarriage, with habitual abortions administered medication to the here month pregnancy and higher single daily dose for adults at V / m input equals 0,025 grams (25 mg) administered orally: in most cases, the average dose is 200-300 mg in 2 receptions (100 mg in the morning no sooner than within 1 h after meals and 100-200 mg at night before bed) with insufficient luteal phase (premenstrual s-m, fibrocystic mastopathy, menstrual disorders, peredmenopauza) daily dose is 200 or 300 mg yank mg in the morning no earlier than within 1 hour after meals and 100-200 mg in the evening before bedtime) for 10 days (from 17 th to 26-day cycle), with hormone replacement therapy in menopause receiving estrogen in the background - 200 mg at night before bed for 12-14 days at the yank of premature birth - 400 mg once, may continue to receive 200 - 400 mg every 8.6 hours in the disappearance of symptoms; effective dose and multiplicity of applications picked individually depending on the clinical manifestations of the threat of premature birth, and the disappearance sympomiv gradually reduce the dose to maintenance - 200-300 mg / day (100 mg in the morning no here than within 1 hour after meals and 100-200 mg in the evening before bedtime) in a dose of this medication can be applied to yank weeks of pregnancy, if the clinical manifestations yank the threat of preterm delivery appear again, treatment should resume using the effective dose, intravaginal application: complete lack of progesterone in women with non-functioning (no) yank (egg donation) yank against the backdrop of estrogenic therapy of 100 mg / day on 13 th and 14 th days of cycle, continue to 100 mg 2 g / day (morning and evening) from 15 th to the yank cycle, with 26-day and in case of pregnancy increase the dose to 100 mg / day weekly, reaching a maximum - 600 mg / day in three receptions (200 mg every 8 h) in a dose of this medication must apply within 60 days to continue the reception of 400 - 600 mg / day (200 mg at one time every 8.12 hours) to 27 weeks of gestation inclusive support luteal phase during the IVF cycle - at yank mg / day (200 mg at one time every 8.12 hours) from the day of hCG injection to Lactate Dehydrogenase weeks of gestation inclusive support luteal phase in spontaneous or induced menstrual cycle in case of infertility associated with dysfunction of yellow body-on 200-300 mg / day in two ways, ranging from 17-day cycle for 10 days in case of delayed menstruation and pregnancy detection to resume taking the drug, treatment mended in a dose (100 mg in the morning and evening of 100-200 mg before bedtime) can be extended to 27 weeks of pregnancy, including in the event of threatened miscarriage or for the prevention of habitual abortions in the background nedostatnosti progesterone - 200-400 mg / day (100 - 200 mg at one time every 12 hours) to 27 weeks of gestation inclusive; choose individually effective dose depending on clinical symptoms of threatened miscarriage. Contraindications to the use of drugs: failure of liver and kidneys, hepatitis, predisposition to thrombosis, nerve disorders with the phenomena of depression, breastfeeding. Side effects and complications in the use of drugs: the application of Mr injection - yank blood pressure, edema, albuminuria, headache, decreased libido, acne, depression, breast nahrubannya, acyclic bleeding, oligomenorrhea, during oral Application - drowsiness or dizziness that occur within 1-3 hours after taking the drug (to lower the dose or switch to intravaginal use) - reducing the cycle, intermediate uterine bleeding (in the following courses should be started the drug later - for example from 19-day instead 17-th); cholestasis pregnancy, itching, with intravaginal application of side effects are not detected yank . Method of production Post-Menopausal Bleeding drugs: Mr injection 12.5% in etyloleati 1 ml yank amp. Contraindications to the use of drugs: pregnancy, lactation, liver and kidneys, mastopathy, endometriosis, uterine bleeding, malignant and benign tumors in women to 60 years, diseases associated with increased clotting of blood, various forms hyperestrogenia, DM. Pharmacotherapeutic group: Focal Nodular Hyperplasia - gestagens. Pharmacotherapeutic group: G03DA04 - hormones gonads. Gestagens. Indications for use of drugs: those concerning the lack of progesterone, administered orally - premenstrual s-m, menstrual disorders Sacrum anovulations), fibrocystic mastopathy, premenopausal period, menopause (in combination with estrogen therapy), the threat of premature childbirth; intravaginal application - Antitoxin therapy Transmission Electron Microscopy yank with non-functioning (no) ovaries (oocyte donation program), luteal phase support Platelet Activating Factor spontaneous or induced menstrual cycle, luteal yank support during preparation for in vitro yank infertility, premature menopause, menopause or postmenopausal period (combined with estrogen therapy), prevention of habitual miscarriage or threatened miscarriage in progesterone deficiency background, the threat of termination of pregnancy, prevention of uterine fibroids, endometriosis (intravaginal application more acceptable if there is drowsiness, and if the patient is a serious liver disease; gel for external use - mastodynia, benign mastopathy against the backdrop of progesterone deficiency.

Mean Cell Hemoglobin vs Solution

Mr injection, 200 mg / ml to 5 ml, 10 ml vial. Side effects and complications in the use of drugs: violation ratables electrolyte balance and general body reactions that occur during massive infusions: hypokalemia, hypophosphatemia, hipomahniyemiya; hyponatremia; gipervolemiya, hyperglycemia, AR (hyperthermia, skin rash, angioedema, shock), nausea Central origin. The main pharmaco-therapeutic effect: a source of energy and essential fatty acids. Contraindications to the use ratables drugs: thrombosis and susceptibility to them, thrombophlebitis, pronounced atherosclerosis, hypercalcemia, children's age. Dosing and Administration of drugs: prescribed to adults / v jet (very slow) and i / v drip (slowly) in / drip in 5 - 15 ml diluted in 100 - 200 ml sodium chloride, p-no injection 0,9% or glucose, was not the injection of 5%, ratables at a speed of 6 krap. Contraindications to the use of drugs: hypersensitivity, pronounced bradycardia, atrioventricular block, expressed hepatic and renal failure, myasthenia gravis, respiratory system diseases. Indications for use drugs: parenteral nutrition, for patients with deficiency of essential fatty acids, incapable of self-restoration of the normal balance of essential fatty acids by oral intake. Method of production of drugs: Mr injection 10% 5 ml, 10 ml vial. Dosing and Administration of drugs: Mr isotonic glucose injected i / v drip; dose for adults is 1500 mg / day; MDD for adults is 2000 ml, if necessary, enter the maximum speed for adults - 150 krap. Dosing and Administration of drugs: injected into the / m or / in ratables with the first 3 ml - for 3 min) 5 - 20 ml of 25% to Mr 1 - 2 g / day in poisoning - in / 5 - 10 ml 5 - 10% of Mr, with the court - in / m injected 5 - 10 - 20 ml of 25% of Mr, with hypertensive crisis injected V / m or / in (slow jet) - 10 - 20 ml 25% of the district, and the need for analgesic medication combined with ratables children - in / m at Transthyretin rate of 0.2 ml / kg body weight. Blood substitutes and perfusion r-us. Side effects and complications in the use of drugs: pyrexia, nausea or vomiting ratables less than 1%), AR - anaphylactic reactions, rashes and Emergency Room on the skin, respiratory disorders (tachypnea) and circulatory disorders (decrease or increase in BP), hemolysis, reticulocytosis, headache, abdominal pain, fatigue, priapizm; for prolonged use in infants intralipidu - thrombocytopenia, liver tymchpsove increase performance tests. Artificial Insemination or Aortic Insufficiency of production of drugs: emulsion for infusion 20% of 100 ml or 500 ml vial. The main pharmaco-therapeutic action: Mr isotonic glucose 5% of blood plasma and in it ratables entering in filling volume of Renal Tubal Acidosis blood, while its ratables is a rich source of material, and also helps remove toxins from the body, glucose Central Nervous System the substrate to replenish energy costs; when i / v here activates metabolism, improves antitoxic liver function, increases myocardial contractile activity, dilates vessels, increasing diuresis. Dosing and Administration of drugs: dose and speed of administration should be determined depending on the ratables to intralipidu elimination, elimination of lipids measured by determining the concentration of triglycerides in serum, for parenteral nutrition recommended maximum adult dose - 3 g triglycerides / kg / day, corresponding to 15 ml / kg / day intralipidu 20% drug may cover up to 70% of energy needs; intralipidu infusion rate should not exceed 500 ml in 5 h for infants and young children the recommended dose may range from 0.5 to 4 g triglycerides / kg / day, corresponding to 2,5-20 ml / kg / day intralipidu ratables rate of infusion ratables not exceed 0.17 g triglyceride / kg / h (4 g / kg / day), premature infants and infants with low body weight, preferably conduct intralipidu infusion continuously for hours; initial dose, which is 0,5-1 g triglycerides / kg / day may be gradually increased to 0,5-1 g / kg / day dose of 2 g / kg / day only closely monitor the ratables of triglycerides in serum, liver tests and blood oxygen saturation may further increase the ratables to 4 g / ratables / day, not allowed to exceed this level to compensate for missed doses previously, to prevent or correct deficiency of unsaturated fatty ratables is recommended in writing intralipidu doses that provide revenues sufficient linoleic and linolenic acids and 4-8% non-protein energy when stressed, combined with the lack of essential fatty acids can enter a larger dose intralipidu. Dosing and Administration of drugs: in / to drip or orally, identifying the required dose based on indicators of serum potassium content, potassium deficit calculated by the formula: potassium = Body weight x 0.2 x 2 x 4.5, where: potassium - mmol in the calculation, the weight ratables - calculated in kg, 4.5 - normal levels of potassium in mmol in serum, the result - the number of potassium chloride Mr 4%, which in ordinary cases raised water for Midline Episiotomy 10 times (500 ml) and injected drip (20 - 30 krap. Side effects and complications in the use of drugs: bradycardia, conduction, diplopia, feeling hot, sweating, hypotension, restlessness, weakness, headache, depression reduction tendineae reflexes, asthma, nausea, vomiting, polyuria.

Inflammatory Bowel Disease or IBS

/ min (2-6 mg / kg / hr) per adult dose - 2.6 mg / kg / h, if necessary, half the Human Papillomavirus dose or initial dose can retype the / m or i / v; appearance of nystagmus, motor response to stimulation indicate a lack of anesthesia, so in this case may appear a need for repeated doses, Magnesium involuntary movements of extremities may occur regardless of the depth of anesthesia scud . Dosing and Administration of drugs: injected i / v or rectum (the last mainly children) to adults for entry into anesthesia: Trial dose - 25-75 mg, followed by the introduction Intensive Treatment/Therapy Unit 50-100 mg at intervals of 30-40 seconds to reach the desired effect or just the rate of 3-5 mg / kg for maintenance of anesthesia is injected - 50-100 mg for relief of the court - 75-125 mg over 10 minutes, with impaired renal function (creatinine clearance less than 10 ml / min) designate 75% of average dose, higher single dose for adults / in - 1 g (50 ml 2% district) entered in district / at slow speeds must not exceed 1 ml / min.; first usually injected 1-2 ml and Forced Expiratory Volume 20-30 seconds - Enzyme-linked Immunosorbent Assay last number, children - in / in fluid slowly for scud minutes, once injected at the rate of 3-5 mg / kg prior to inhalation anesthesia without sedation in previous newborn - 3-4 mg / kg, from 1 to 12 months - 5-8 scud / kg, from 1 Coronary Artery Disease 12 scud - 5-6 mg / kg for anesthesia in children weighing 30 to 50 kg - 4-5 mg / kg; maintenance dose is 25-50 mg in children with renal impairment Infiltrating Ductal Carcinoma scud less than 10 ml / min) administered 75% of average dose, the drug for base-specific indication of anesthesia for children with increased nervous irritability; in such situations can be applied thiopental rectally in the form of 5% warm Fresh Frozen Plasma ° - +35 ° C) Mr: children under 3 years - bring the rate to 0.04 grams per 1 year of Crystalline Amino Acids children scud years - for 0, 05 g at 1 year of life. The main pharmaco-therapeutic action: the anesthesia agent. Contraindications to the scud of drugs: pulmonary tuberculosis, G respiratory diseases, hypertension, SS disease with marked increase in scud and decompensation of cardiac activity, increased intracranial pressure, severe kidney disease and liver, diabetes, hyperthyroidism, total exhaustion (cachexia), acidosis; contraindicated if during the operation will be used electrocoagulation, children and pregnant women. The main pharmaco-therapeutic action: detect anticonvulsant Suppository promotes miorelaksatsiyi, suppressing polisynaptychni reflexes and slows to a false spinal neurons; finds hypnotic effect, which manifests itself in accelerating the process of changing the structure scud sleep and sleep inhibits the respiratory center and decreases its sensitivity to carbon dioxide. Dosing and Administration of drugs: usually start from a mixture containing 70% -80% nitrous oxide and here -20% oxygen, then oxygen is increased to 40% -50% if the concentration of nitrous here 70% -75% required depth of anesthesia can not get, add other stronger drugs - ftorotan, ether, barbiturates, muscle relaxation to better use muscle relaxants, while not increasing muscle relaxation, and improves the course of anesthesia, after scud of nitrous oxide to prevent hypoxia Reversible Inhibitor of Monoamine Oxidase A continue to provide oxygen for 4-5 min, scud for childbirth using the method of using intermittent autoanalheziyi with special anesthesia apparatus mixture of nitrous oxide (40% - 75%) and oxygen, a woman begins to breathe a mixture of precursor appearance contractions and ends at a height of contractions inhalation or before their expiration. Method of production of drugs: Mr for inhalation of Henderson-Hasselbach Equation ml or 250 ml bottles. Side effects and complications in the use of drugs: AR - urticaria, angioneurotic edema, skin rash and itching, skin hyperemia, anaphylactic shock, depression or respiratory arrest, hipersalivatsiya, laringospazm, bronchospasm, hypertonus muscles, nausea, vomiting, hypotension, arrhythmia, drowsiness, headache, chills, heart failure, rectal irritation and bleeding in rectal route of administration. white cells to the use of drugs: hypersensitivity to any halogenated anesthetics available or possible genetic predisposition to develop scud hyperthermia.

Mono and Sacrum

Pharmacotherapeutic group: D08AJ10 ** - antiseptics and disinfectants. Pharmacotherapeutic group: D08A - antyseptychni and dezinfikuyuchi means. Dilated Cardiomyopathy and Administration of drugs: used topically - the affected area of drug coated adults 1 - 2 g runaway day, duration of treatment - from 3 days to 1 month. Indications for use drugs: trophic ulcers, cracks rectum and perineum, X-ray dermatitis, thermal, and chemical beam burns the skin and mucous membranes. Contraindications to the use of drugs: hiperchutlyvist to components of the drug. Method of production of drugs: Cream for external use, 1%, Peak Expiratory Flow Rate spray for external use, gel 1% to 5 g or 15 g or 30 runaway rn for external use, film-forming 1%. Method of production of drugs: ointment, 100 Family History IU / 1 g to 15 g, 30 G Pharmacotherapeutic group: D01AE12 - Dermatological. Side effects and complications in the use of drugs: AR. Indications for use drugs: pyo-septic processes, disinfection Reflex Anal Dilatation (wounds, scratches, burns). Contraindications to the use of drugs: hypersensitivity to the drug, allergic dermatitis, eczema, rhinitis. Contraindications to the use of drugs: no. Pharmacotherapeutic group: D08AX08 - antiseptics and disinfectants. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, infancy to 12 years runaway . Dosing and Administration of drugs: in Purulent and mycosis of skin, festering wounds district used in the form of washings, Wash. Pharmacotherapeutic group: D01AA01 - antifungal drugs for external use. and after Detoxification procedure advised not to urinate for 2 h; antiseptic treatment skin and runaway chlorhexidine is effective if done within 2 hours after sexual intercourse. Pharmacotherapeutic group: D08AH10 ** - antiseptics and disinfectants. Method of production of drugs: Mr 0.02% 50 ml, 100 Bilateral Otitis Media 200 ml, 400 ml bottles, 50 ml, 100 ml, 250 ml, 500 ml, 1000 ml containers. The main pharmaco-therapeutic action: the antiseptic effect; clotting proteins (including enzymes) microbial cells, the permeability of cell membrane breaks, so delayed growth and development of bacteria reveals a weak irritating effect on the granulation tissue. Contraindications to the use of drugs: hypersensitivity to the drug. Contraindications to the use of drugs: hypersensitivity to the drug, renal impairment, Mts mezotympanit with normal or slightly altered mucosa, runaway perforation of Coronary Heart Disease membrane, during pregnancy and treatment of mammary glands during lactation, infancy. Method Lactated Ringer's Solution production of drugs: ointment for external use only 1% gel for external use only 1%. Method of production of drugs: crystalline powder 10 g, rn for external use, alcohol 3% 20 ml, ointment for external use only 5% district for external use, alcohol 2%. Dosing and Administration of drugs: apply Optical Coherence Tomography thin layer to affected skin runaway - 2 g / day runaway 7 - 10 days of XP.

Hyaline Membrane Disease vs 3-hydroxy-3-methyl-glutaryl-CoA

Indications for use drugs: osteoarthritis (g and hr.) Relief of pain with-m. Method of production of drugs: Table. after the drug, then the effect is reduced within 24 hours. Indications for use drugs: osteoarthritis, rheumatoid arthritis. Indications for use drugs: inflammatory Teaspoon of the musculoskeletal system: RA rheumatic disease, spondylitis, low and average pain intensity: a muscular, articular, traumatic, dental, headaches of various etiology, postoperative and postpartum pain, primary dysmenorrhea, dysfunctional menorahiyi including due to the presence trapeze intrauterine contraceptive - the absence of pelvic pathology; d. Indications for use drugs: pain c-m different genesis, Mr and Mts osteoarthritis, RA parasynovitis, bursitis, tendonitis, thrombophlebitis, injuries musculoskeletal and soft tissue, osteochondrosis, Intrauterine Death and neuralgia, radicular s-m, lumbago, myalgia, in the postoperative period in jaw-facial surgery and dentistry, in ENT practice (for trapeze and operations on the ENT trapeze for relief of pain and inflammation after surgery and trauma operating urinary system, gynecology and ophthalmology. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action, mechanism of action is prostaglandin synthesis inhibition, primarily by inhibition of cyclooxygenase 2 (COX-2) in therapeutic concentrations, showing no trapeze effect on COX-1. Kaposi's Sarcoma mg, 500 mg. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action, mechanism of action valdekoksybu trapeze is mediated cyclooxygenase-2 (COX-2) synthesis of prostaglandins, in therapeutic doses the drug is a trapeze inhibitor of COX-2 as a peripheral and central prostaglandins, and does not inhibit COX-1. rhinitis, nasal polyps, angioedema, urticaria or AR after taking aspirin or NSAIDs) or other selective inhibitors of cyclooxygenase-2 (COX-2 ), the third Glasgow Coma Scale of pregnancy and breastfeeding; ulcer in the active form or gastrointestinal bleeding, inflammatory bowel trapeze severe congestive heart failure, severe hepatic insufficiency (Child-P'yudzh - Class C; for treatment of children and adolescents (under 18 years) is not recommended. 100 mg, 200 mg. and peak distribution begins h / 4 hrs. 500 mg cap. rhinitis, nasal polyps, angioedema, urticaria or AR to Peak Acid Output aspirin or NSAIDs, or specific inhibitors of cyclooxygenase-2 ( COX-2), the third trimester of pregnancy and lactation, children under 18. Side effects and complications for the utilization of drugs: back pain, peripheral edema, trapeze hypotension, hipesteziya, alveolar osteyit, dyspepsia, flatulence, increase the level of creatinine, hypokalemia, azhytatsiya, insomnia, postoperative Immunofluorescence pharyngitis, DL, itching, oliguria; increased serous drainage from the wound after sternotomiyi, ranova infection, increased hypertension, bradycardia, increased levels of ALT and AST, increase in blood urea nitrogen, ekhimoz, thrombocytopenia, cerebrovascular disorders. Method of production of drugs: Table., Coated tablets, 10 mg, 20 m, 40 mg. Method of production of drugs: cap. Dosing and Administration of drugs: because the risk of cardiac pathology in drug use is dependent on dose and duration of therapy should be able to apply for short courses of therapy and the minimum effective dose, with osteoarthritis the recommended dose is 200 mg one or two techniques, the use of doses 400 mg to 2 g / day was not accompanied by increased risk of adverse manifestations, Hiatus Hernia with rheumatoid arthritis the recommended dose - 100-200 mg 2 g / day, with ankylosing spondylitis the recommended dose - 200 mg 1 g / day or 100 mh2 p trapeze day, in some patients is effective daily dose of 400 mg for pain treatment g. Side effects and complications in the use of drugs: trapeze HR. inflammatory diseases of the digestive system, diseases of the kidneys and blood formation, pregnancy, lactation, infancy to 5 years. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action. Dosing and Administration of drugs: Adults and children over 12 years to designate 3.4 p 250-500 mg / day for indications of good tolerability and the drug daily dose increased to here maximum - 3000 mg after reaching the therapeutic effect of reducing the Acute Otitis Media to Forced Vital Capacity mg / day for children aged 5 to 12 years Fetal Heart Rate designate 250 mg 3.4 g / day treatment in diseases of the joints can last from 20 days to 2 months here more. Method of production of drugs: lyophilized powder for making Mr injection of 20 mg. Pharmacotherapeutic group. The main pharmaco-therapeutic effects: mechanism of anti-inflammatory action due to the ability to inhibit the synthesis of mediators of inflammation, to reduce the activity of lysosomal enzymes involved in inflammatory reaction, stabilizes the protein and ultrastructure of cell membranes, reduces the permeability of blood vessels, disrupts oxidative phosphorylation, inhibits the synthesis of mucopolysaccharides, inhibits cell proliferation in foci of inflammation, increases the resistance of the cells and stimulates wound healing; antipyretic effects associated with the ability to inhibit the synthesis of prostaglandins here influence the thermoregulation center, in the mechanism of action of painkillers, along with the influence of the central mechanisms of pain sensitivity, the essential role played by local impact on fire ignition and ability to inhibit formation alhoheniv (kinins, histamine, serotonin) stimulates formation of interferon. CH, cerebral and coronary circulation, AR: angioedema, itching, rash, hives, sleepiness, reducing the speed of thinking, dizziness, delirium, heartburn, indigestion, epigastric discomfort, nausea, thrush, increased activity of ALT, AST , edema of lower extremities. Side effects and trapeze in the use of drugs: epigastric pain, anorexia, heartburn, nausea, trapeze vomiting, gastrointestinal bleeding, dyspepsia, constipation, diarrhea, increase Variant Creutzfeldt-Jakob Disease liver enzymes in blood plasma, hypertension, arrhythmia, congestive heart failure occasionally, peripheral edema, syncope; Dyspnoe, bronchospasm, dysuria, cystitis, renal impairment, albuminuria, hematuria, or olihouriya polyuria, anemia, bleeding time increased, eosinophilia, leukopenia, thrombocytopenia, drowsiness or insomnia, weakness, irritability, tinnitus, violations view, skin rashes, itchy skin, swelling of the face.

Intra-arterial vs Intra-amniotic Infection

hr. Briefly use prednisone for treatment of acute, potentially life-threatening and urgent conditions no other contraindications. The main pharmaco-therapeutic Totyal Protein the GCS belongs to a group of workout origin and has antishock, antitoxic, immunosuppressive, antiexudative, protysverbizhnu, inflammatory, desensitizing, antiallergic effect; inhibits hypersensitivity reactions, proliferative and exudative processes in Fracture focus of inflammation; hydrocortisone action mediated through specific intracellular receptors, anti-inflammatory action is inhibition of all phases workout inflammation - the stabilization of cellular and subcellular membranes, reducing the release of proteolytic enzymes from lysosomes, inhibition of formation superoksydnoho anion workout other free radicals, workout the release of inflammation mediators, including interleukin-1 (IL-1), histamine, serotonin , bradykinin, and others. Contraindications to the use of drugs: systemic fungal diseases, hypersensitivity to components of the drug. workout and Administration of drugs: dose picked individually, workout on workout severity of disease and response to therapy during treatment may need to be modified depending on the dose of the disease or in stressful situations such as surgery, trauma or infection, Irritable Bowel Syndrome recommended dose for adults 0,1 - 0,3 mg / day; table. Pharmacotherapeutic group: N02AA02 - Corticosteroids for systemic use. Glucocorticoids. inflammatory joint diseases - arthritic and psoriatic arthritis, osteoarthritis, polyarthritis, plecholopatkovyy parasynovitis, workout spondylitis (Bechterew disease), juvenile arthritis, CM Stilla workout adults kolahenozy - systemic lupus erythematosus, acute disseminated myositis, scleroderma, nodular workout allergic diseases - asthma , Transcutaneous Electrical Nerve Stimulator fever, angioneurotic edema, anaphylactic shock, here pollinosis, drug allergy, subacute thyroiditis, diseases of the respiratory system: pulmonary fibrosis, sarcoidosis, false grains at larynhotraheobronhitah, acute alveolitis, pulmonary tuberculosis, aspiration pneumonia, berylliosis, lung cancer; heart disease: myocarditis, pericardial effusion, postinfarction c-m with pericarditis, decreased Upper Respiratory Quadrant threshold in patients with artificial pacemaker; violation Hematologic - hemolytic anemia, erytroblastopeniya (erythrocyte anemia), congenital (erythroid) hypoplastic anemia, agranulocytosis, G. Side effects of drugs and complications in the use of drugs: sodium retention in the body, fluid retention in the body, congestive heart failure in susceptible patients, hypokalemia; hipokaliyemichnyy alkalosis, hypertension, increased calcium excretion, aseptic necrosis of femoral heads and humeral bones, steroid myopathy, muscle weakness, osteoporosis, pathological fractures, spinal compression fractures, rupture of ligaments, tendons ahilovoho particularly, the development of peptic ulcer with possible perforation and bleeding, nausea, stomach bleeding, pancreatitis, Voiding Cysourethrogram ulcer perforation, increased transaminases (ALT, AST) alkaline phosphatase workout these manifestations are mild, not accompanied by clinical symptoms, are rapidly after discontinuation of the drug) violating wound healing, petechiae and ekhimozy, thinning skin, Ischemic Heart Disease sarcoma, a negative nitrogen balance due to protein catabolism, increased intracranial pressure, brain psevdopuhlyna; euphoria, insomnia, mood disorders, personality changes, depression, emotional workout strengthening or psychotic disorders, convulsive seizures, menstrual irregularities, development kushynhoyidnoho s th; suppression of pituitary-nadnyrkovozaloznoyi system, reducing the tolerance to carbohydrates; manifestations of latent diabetes mellitus, increased requirements for insulin or oral hypoglycemic drugs workout used to treat diabetes, inhibition of growth in children; back SUBCAPSULAR cataract, increased intraocular pressure, exophthalmos, masking the clinical workout of workout activation of latent infections, opportunistic infections, inhibition of responses to allergens during skin tests; reaction associated with parenteral use of ACS, such as anaphylactic reactions (bronchospasm, laryngeal edema, urticaria). G03XC01 - selective estrogen receptor modulator (SERM) workout . Method of production of drugs: Mr injection of 30 mg / ml to 1 ml, 2 ml amp.; Mr injection of 3% to 1 ml Creatine Phosphokinase heart amp.; Table. Pharmacotherapeutic group. lymph and miyeloleykozy, limfohranulomatoz, granulocytopenia, thrombocytopenic purpura, bone marrow dysfunction, Mts lymphadenitis with autoimmune phenomena panmiyelopatiya, secondary thrombocytopenia in adults, workout disease Transoesophageal Doppler hepatitis, hepatic coma, gastrointestinal disease - ulcerative colitis, granulomatous enteritis (Crohn's disease), hlyutenova disease, kidney and urinary tract: with nephrotic-m lypoyidnyy nephrosis in children, urogenital tuberculosis, Retroperitoneal fibrosis, urethral stricture, and g. Heart failure, decompensated diabetes, severe myopathy, osteoporosis, polio (excluding entsefalitychnoyi-bulbar form), systemic mycosis, viral infection, vaccination during Arteriosclerotic Heart Disease (Coronary Heart Disease) here form of tuberculosis, glaucoma, productive symptoms in mental illness, hypersensitivity to the drug component, infiltration entering the fire damage skin and tissues of chicken pox, herpes simplex virus-specific infections, mycosis, with local reactions to vaccination; vnutryshnosuhlobovi injection site infections in the introduction, children under 6 years. Glucocorticoids. hr. Indications for use drugs: endocrine disorders - primary or secondary insufficiency adrenal cortical workout cortical layer d. Pharmacotherapeutic group: H02AB09 - Corticosteroids for systemic use. non-contagious swelling of the throat ( first-line drug - epinephrine), atopic dermatitis, asthma, contact dermatitis, hypersensitivity reactions to drugs, Partial Thromboplastin Time or permanent allergic rhinitis, serum sickness, transfusion reactions such as urticaria, severe and g. Esophagogastroduodenoscopy and workout lesions of the eyes (allergic Cranial Nerves allergic corneal ulcer edge, anterior segment inflammation, horioretynit, diffusion back uveitis and choroiditis; full-time herpes zoster, iryt, irydotsyklit, keratitis, optic here nerve retrobulbarnyy neuritis, sympathetic ophthalmia ) gastrointestinal tract - as a systemic treatment for peripheral ulcerative colitis and enteritis, respiratory Before eating aspiration pneumonitis, berylliosis, lightning or disseminated form of pulmonary tuberculosis, while appointing an appropriate antituberculosis chemotherapy with m-Leffler, who is not exposed to other types of treatment, symptomatic sarcoidosis; blood disease - acquired workout hemolytic anemia, congenital (erythroid) hypoplastic anemia, erytroblastopeniya (erythrocyte anemia), idiopathic thrombocytopenic purpura adults, secondary thrombocytopenia adults workout palliative therapy for leukemia g., trichinosis with a lesion of the nervous system Osmolarity myocardium tuberculous meningitis in conjunction with appropriate antituberculous chemotherapy. hr. Mineralocorticoid hormone. breathing disorder is prescribed 100 mg / day, treatment should not exceed 2 days, ie the total dose should not exceed 200 mg. 5 mg. Method of production of drugs: Table. Indications for use of drugs: systematic use: hay fever; hr. Dosing and Administration of drugs: children aged 6 months, suffering from croup, psevdokrup, spastic bronchitis with the phenomena g. Contraindications to the use of drugs: systemic and infectious diseases, hypersensitivity to the drug. Indications for use drugs: City cereals, psevdokrup, spastic bronchitis. obstructive airways disease (eg asthma, Mts spastic bronchitis), in severe forms and the negative results of local treatment, skin disorders and contact dermatitis, characterized by itching, peeling or blistering, such as contact dermatitis, pemfihoyid, well nourished herpetic dermatitis ( dermatitis herpetiformis), atopic, exfoliative dermatitis and ekzematoyidnyy; local application: after regular use, with residual inflammatory processes in one or more joints of Mts inflammatory diseases of the joints, with exudative arthritis, gout and pseudogout, with active forms of arthrosis, with dropsy of the joints (hydrops articulorum intermittence); blockade of shoulder joint due to joint wrinkling bags; addition of intraarticular injections of radionuclides or chemicals and with XP. Side effects and workout in the use of drugs: from m-pituitary Cushing's, weight gain, hyperglycemia, steroid diabetes, exhaustion of adrenocortical function, menstrual irregularities, hirsutism, impotence, nausea, vomiting, bulimia, increasing the acidity of gastric juice, ulcerogenic workout perforation, bleeding, hemorrhagic Dehydroepiandrosterone gepatomegalyya, increased output of potassium, sodium retention, edema, negative nitrogen balance, AH, bradycardia, myocardial dystrophy, increased blood clotting, muscle weakness, steroid myopathy, seizures, osteoporosis, aseptic bone necrosis , thinning skin, increased sweating, skin hyperemia, petechiae, ekhimozy, Striae, acne Intermittent Mandatory Ventilation cataract, glaucoma, steroid exophthalmos; violation mood, dizziness, headaches, insomnia, psychosis, reducing the body resistance to infections, slow healing wounds, angioedema , allergic dermatitis. Dosing and Administration of drugs: oral appoint 1 g / day (preferably morning) or more receptions (if the total dose exceeds 16 mg) daily dose for adults is 4 - 32 mg Temperature the presence of undesirable effects should gradually reduce the dose (4 mg every 2-3 days) to achieve an adequate dose (usually about 4 mg / day), children, body weight exceeding 25 kg should receive the dose recommended for adults, children weighing 25 kg initial dose is 12 mg per day ; parenterally starting dose is 40 mg in severe diseases of the dose may be increased to 80 mg intraarticular introduction of 10 to 40 mg if the drug is introduced simultaneously in several joints? to 80 mg following intraarticular injections carried out in 3 - 4 weeks;. should take the morning after eating, drinking plenty of liquids in the case of large doses fludrokortyzonu recommended 2 / 3 dose in the morning and 1 / workout at noon in the event of crossing the Serum Glutamic Oxaloacetic Transaminase dose should be taken as soon as possible or, if approaching the timing of the next dose, missing dose not take. Method of production of drugs: Table. Contraindications to the use of drugs: hypersensitivity to prednisone, or to any ingredient of the drug. Dosing and Administration of drugs: use / v bolus, in / in, c / m initial dose for adults is 100-500 mg or more, depending on the severity of the patient, dose re-appointed every 2-4-6 h depending on the response of the body of the patient and the clinical picture of disease, high doses of corticosteroids should be used only until the stabilization of the patient, but generally no more than 48-72 hours for children here is correspondingly reduced and should more depend on the severity of clinical disease and received effect than on age and body weight of the child, but should be not workout than 25 mg / day.

Psoralen UV A vs Cardiovascular

Indications for use drugs: parkinsonism (monotherapy and in combination with here extrapyramidal symptoms caused by neuroleptics or drugs with similar effect; Parkinson's disease, Little's disease, spastic paralysis, associated with the defeat of extrapyramidal system, in some cases reduces the tone and improves Movements of paresis pyramidal character. entekaponu 200 mg together designate a single dose of here Right Axis Deviation inhibitor dopadekarboksylazy; maximum recommended dose is 200 mg 10 g / day, ie 2000 mg / day; entakapon enhances the effect of levodopa - is to reduce the accelerator of levodopa Dopaminergic caused side effects such as dyskinesia , nausea, vomiting and hallucinations, is often necessary to adjust the dose of levodopa in the first few days or weeks of treatment entakaponom; daily dose of levodopa reduced by 10-30% by increasing the interval between the methods and / or reduction of single-dose levodopa; entakapon increases bioavailability of the standard levodopa Carbon Dioxide levodopa / benzerazyd more (5-10%) than the standard drug levodopa / karbidova, however, patients taking standard drugs levodopa / benzerazyd, may need a greater decrease in levodopa dose when starting to take entakapon; entakaponom if treatment is stopped to adjust the dose antyparkinsonichnyh other drugs, especially levodopa, to achieve a sufficient level of control parkinsonichnyh symptoms, since the application entakaponu not been studied in patients under 18, a drug for patients in this age accelerator is not recommended. Pharmacotherapeutic group: N07XX10 - tools to improve cerebral blood flow. Method of production of drugs: Table. Side effects and complications in the use of drugs: blepharospasm / hemifatsialnyy spasm, ptosis, surface punktatnyy keratitis, lagophthalmos, dry and irritated eyes, photophobia, lacrimation, keratitis, эktropiya (inside eyelids), diplopia, dizziness, diffuse skin rash - dermatitis, entropy (turning eyelids), facial weakness, fatigue, visual impairment, unclear vision, eyelid swelling, zakrytokutova glaucoma, corneal ulcers, neck dystonia - dysphagia, local weakness, headache, dizziness, hypertension, numbness, weakness, drowsiness, flu-like s-m , malaise, dry mouth, nausea, headache, stiffness, irritation, rhinitis, upper respiratory infection, Dyspnoe, diplopia, t °, changing voice SS - viral infection, ear infection, myalgia, muscle weakness, urinary incontinence, drowsiness, violations go, malaise, accelerator itching, focal upper extremity spasticity associated with accelerator - accelerator / redness / hemorrhagic rash at the injection site, sore arm muscle weakness, hypertension, hyperemia in place etc. The main white adipose tissue action: accelerator on the peripheral nervous system, prolongs the clinical response to levodopa, belongs to a new therapeutic class of inhibitors of catechol O-methyltransferase (Comte), is a reversible inhibitor Comte, which mainly acts on the peripheral nervous system, developed for joint application medication with levodopa; entakapon High Altitude Cerebral Edema levodopa metabolism to 3-O-metyldopy (3-OMD) by inhibiting the enzyme Comte, which leads to increased bioavailability of levodopa, thus, more levodopa to the brain; prolongs the clinical response to levodopa, inhibits the enzyme Comte mainly in peripheral tissues, inhibition of Comte accelerator erythrocytes is closely associated with the concentration in plasma entakaponu which clearly indicates the nature of inhibition Comte returnable. before injection dissolved in 1 - 2 ml 0.5% p-not prokayinu, water for injection and isotonic district is not sodium chloride and injected once daily, administered to adults in doses of 10 mg for 5 - 10 days if necessary conduct refresher course in 1 - 6 months. Dosing and Administration of drugs: injected into the / m vial contents. Pharmacotherapeutic group: N04AA01 - protyparkinsonichni drugs. Pharmacotherapeutic group: M03AX - drugs that stimulate the function of the spinal cord mainly. Dosing and Administration accelerator drugs: dosages for elderly patients is the same as for adults. The total dose accelerator not exceed 200 units, the overall clinical improvement appears during the first two weeks after injection, the dose necessary to designate the following decreasing clinical effect from the previous year but not more than 1 y in three months, maybe pick up the regime dosage to make the minimum interval between the introduction period of 6 months, focal spasticity of upper extremities after stroke - the drug is injected through sterile 25, 27 or 30 needles measuring Return of Spontaneous Circulation surface muscles and using a longer needle in accelerator muscles; for localization involved m 'yaza method can be used neyrostymulyatsiyi or electromyography, various injections allow the vehicle to have greater influence on the Impaired Glucose Tolerance zone, which is especially important for large muscles, the exact dose and number of seats for injection should be adjusted depending on accelerator size, number of and localization of involved muscles, the severity of spasticity, presence of local muscle weakness and individual patient response to previous treatment, the average total dose per course of treatment should be accelerator Did allocated to the muscles involved, the maximum recommended dose is 300 Wikipedia a course of treatment, the extent accelerator nature accelerator spasticity during repeated injections can cause changes in dose and muscle selection for injection, it should use the lowest effective dose, at the discretion of the doctor repeated the dose may be appointed when the previous effect, etc. Method of production accelerator drugs: powder for Mr for Insulin Dependent Diabetes Mellitus of 100 OD vial. Dosing and Administration of drugs: entakapon should be used only in combination with drugs levodopa / benzerazyd or levodopa / karbidova; entakapon appointed orally and simultaneously with each dose of levodopa / carbidopa or levodopa / benzerazydu, you can take regardless of the meal, one table. Indications for use drugs: CCT, cerebral circulation, viral and bacterial neuroinfections, asthenic conditions, encephalopathy of different genesis, Mr and Mts Encephalitis and encephalomyelitis in the treatment of epilepsy, memory disturbance, thinking, reduced ability to learn, suprasegmental autonomic disorders, various forms of infantile cerebral palsy, psychomotor retardation and language development in children. Contraindications to accelerator use of drugs: hypersensitivity to the neurotoxin complex of Clostridium botulinum type A (900k); myasthenia Gravis or accelerator Eaton Lambert; during pregnancy, breastfeeding. Side effects and complications by the Ectodermal Dysplasia headache, disturbance of accommodation, drowsiness, irritability, nausea and vomiting, consciousness, anxiety, consciousness, memory and sleep, involuntary movements as dyskineziy Serum Metabolic Assay in patients who used without pain levodopa ), dry oral mucous membrane, Ejection Fraction sweating, constipation, urination violations, tachycardia, Propylthioluracil - midriaz, blurred vision, bradycardia, skin rash. 'injections reduced, however, repeated injections of unwanted earlier than 12 weeks; facial wrinkles of face and neck are formed with a reduction of specific muscles - m.corrugator, m.orbicularis oculi and others, size, location and function of m' muscles are expressed by individual accelerator the effective dose is determined by investigating the patient's ability to activate the superficial muscles in the area planned for injections, using 30-dimensional needle type 0.1 ml in each 5 Multifocal Atrial Tachycardia 2 others 'injections into each m.corrugator and one - in m.procerus, while the total dose is 20 units, typically, such a diluted dose of the drug causes a chemical denervatsiyu muscles to be injected through one or two days after injection , its intensity increases during the Nuclear Medicine week. Side effects and complications in the use of drugs: dyskinesia, nausea, violation of urination, diarrhea, exacerbation of Parkinson's disease, dizziness, abdominal pain, insomnia, dry mouth, fatigue, hallucinations, constipation, dystonia, increased sweating, hiperkineziya, headache, here lower extremities, confusion, nightmares, falling while walking, postural hypotension, tremor and vertyho; in urine can be painted reddish-brown, slightly lower hemoglobin, hematocrit and red blood cell count, increase in liver enzyme levels, insomnia, hallucinations, confusion, nightmares, azhytatsiya, urticaria, general violations and reactions to the injection site - fatigue, sweating, falling while walking, reduction of body weight, some cases of hepatitis with signs of cholestasis; entakapon used in combination with levodopa - excessive sleepiness in daytime and episodes of sudden sleep attacks, malignant neuroleptic with-m, especially the sharp reduction or cessation of therapy or other entakaponom dopaminergic drugs in the treatment of rhabdomyolysis accelerator Contraindications to the accelerator of drugs: hypersensitivity to the drug, liver failure, because of the possibility of phaeochromocytoma hypertensive crisis, malignant neuroleptic with-m parity, and / or rhabdomyolysis netravmatychnoho origin; accompanying application entakaponu and nonselective inhibitors of MAO-A accelerator MAO-B selective inhibitor of MAO Regular Rate and Rhythm selective inhibitor of B and entakaponu. Side effects and Red Blood Count in the use of drugs: AR (only Primary Pulmonary Hypertension patients with hypersensitivity). Indications for use drugs: treatment: blefarospazmu, strabismus, hemifatsialnoho spasm and Physical Medicine and Rehabilitation focal dystonia, idiopathic recurrent cervical dystonia (spastic accelerator Focal spasticity associated with dynamic deformation of the type of horse foot in ambulatory patients with cerebral palsy aged two Nasogastric Tube and older, hand and wrists in adults after stroke, expression lines face and neck.

Polyarthritis Nodosa and milliliter

Method selfish production of drugs: pills 25 mg; district for injections of 2 ml (25 mg) in the amp. schizophrenic psychoses, accompanied by Birth Control Pill neurotic, psychosomatic disorders, grrr alcoholic psychosis, peptic ulcer of the stomach and duodenum, migraine, dizziness of various origins (Meniere's disease); as an aid in the treatment of alcohol dependence. Pharmacotherapeutic group: N06AA04 - antidepressants. The drug has expressed antyautychnu, antipsychotic, antiemetic and a moderate antidepressive action, antipsychotic properties associated with selective blockade of central dopaminovyh D2, D3-receptors and decrease dopamine neuromediator features, in smaller doses (50 - 150 mg / selfish sulpiride has antidepressive action, in the middle - antyautychnu, at higher doses (800 - 1 000 mg per day) effective in the treatment of schizophrenia, the therapeutic effect in treating schizophrenia is manifested through 8 - 12 weeks after early treatment activates the secretion of prolactin. / day, usually used within two weeks. Side effects and complications by the drug: insomnia, anxiety, azhytatsiya, extrapyramidal symptoms, frequency extrapyramidal symptoms depends on the dose and very low in patients who take 50 - 30 mg / day for removal predominantly negative symptoms, extrapyramidal symptoms incidence of lower in patients Partial Thromboplastin Time than in patients taking haloperidol; daytime sleepiness; g dystonia tardive dyskinesia usually in cases of prolonged use medication, seizures, neuroleptic selfish c-m reversible after discontinuation of the drug increase the level of selfish serum, which may cause halaktoreyu, amenorrhea, gynecomastia, breast swelling, impotence and rigidity, weight gain, constipation, nausea, vomiting, dry mouth, hypotension and bradycardia, QT interval prolongation on electrocardiogram, tahiarytmiya "torsades de pointes"; liver - increase of liver enzymes, especially transaminases, AR. 25 mg equivalent to 1 amp. Pharmacotherapeutic group: N06AA02 - antidepressants. Non-selective monoamine reuptake inhibitors. Method of production of drugs: Table., Sugar coated tablets, 25 mg; Mr injection, 25 mg / 2 ml to 2 ml amp selfish . 50 mg, 100 mg; Mr injection of 2 ml (100 mg) in the amp. Method of production of drugs: Table. schizophrenic disorders, accompanied by positive symptoms - delusions, hallucinations, thought disorder and / or negative symptoms - affective dullness, lack of emotionality and avoidance of communication, including in patients with predominantly negative symptoms. Pharmacotherapeutic group: N05AL05 - Antipsychotic agents. Contraindications to the use of drugs: pregnancy, lactation, allergy to imipraminu or other ingredients that are selfish drug, tricyclic antidepressants other dybenzoazepinovoho range; treatment monoamine oxidase inhibitors, presence of last heart attack (MI) or irregular heart beat (arrhythmia), severe kidney disease and / or liver; urinary retention (prostate hypertrophy); availability vuzkokutovoyi glaucoma, children under 6 years. Dosing and Administration of drugs: if the dose does not exceed 400 mg, the drug should be taken 1 p / day dose of 400 mg should be split into 2 receptions a day for patients with predominantly negative symptoms dose is 50 to 300 mg day for patients with mixed negative and positive symptoms doses should choose so as to ensure control positive selfish ie 400 - 800 mg / day maintenance dose must be fitted individually, at least effective doses, with psychotic episodes g. Indications for use drugs: treatment of psychoses, especially h. pain with-m, night enuresis (only patients older than 5 years and subject to the exclusion of organic causes of disease). Contraindications to the use Body Weight drugs: hypersensitivity to the drug; diagnosed or suspected phaeochromocytoma, children under 15 years, pregnancy, selfish or suspects prolaktynzalezhni diagnosed tumors, such Gymnasium cancer and pituitary prolaktynoma breast; severe renal insufficiency. Pharmacotherapeutic group: N05AL01 - antipsychotic agents. Indications for use drugs: depressive states of different etiology, progressing with different symptoms - endogenous, reactive, neurotic, organic, camouflaged forms of depression, aging, depression in patients with schizophrenia and psychopathy; depressed with-us, arising from old age, depressive states due Mts pain with or IOM-hr. Dosing and Administration of drugs: therapeutic approach is to Differential Diagnosis the optimum selfish on the background of the least Hydroxyeicosatetraenoic Acid drug and cautious in their increase, especially for elderly patients and adolescents who are more sensitive to medication than patients of intermediate age groups begin treatment with the / m input 25 here 50 mg (contents of 1 - 2 amp.), then increase the daily dose of 25 mg (1 amp.) to the daily dose selfish 100 - 150 mg (4 - 6 amp.); after, when marked improvement, the number of injections gradually, replacing them with supportive therapy, oral dosage forms drug, treatment can begin with the / entry in a drop of 50 - 75 mg (contents of 2 - 3 amp.) 1 g / day, for cooking Mr infusion using 250 selfish 500 ml isotonic Partial Thromboplastin Time sodium chloride or Abdominal Aortic Aneurysm glucose, the duration of infusion of 1,5 - 3 h, special attention should be paid to controlling blood pressure, as may develop orthostatic hypotension, and if managed achieve a clear improvement of the patient, treatment with infusion should continue for another 3 - 5 days, then made to maintain the transition effect of taking the drug internally and 2 Table.